CTOs on the Move


 
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.equilliumbio.com
  • 2223 Avenida De La Playa Suite 105
    La Jolla, CA USA 92037
  • Phone: 858.412.5302

Executives

Name Title Contact Details

Funding

Equillium raised $30M on 02/04/2021

Similar Companies

Helm Pharmaceuticals

Helm Pharmaceuticals is a Chappaqua, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triad Life Sciences

Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months – Learn More >> Triad Life Sciences® introduces InnovaMatrix™Technology Platform, a next-generation extracellular matrix (ECM) product that advance...

A2 Biotherapeutics

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.

Setren, Smallberg and Associates

Setren, Smallberg and Associates is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.